4.6 Article

Development of a novel thermal-sensitive multifunctional liposome with antibody conjugation to target EGFR-expressing tumors

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2018.10.006

关键词

EGFR; TSML; Doxorubicin; Erbitux; AuNR@MnMEIO; MRI

资金

  1. Ministry of Science and Technology [MOST 106-2113-M-009-023, MOST 105-2923-M-009-002-MY2, MOHW 105-TDU-B-212-134005]
  2. Ministry of Health and Welfare of the Republic of China [MOST 106-2113-M-009-023, MOST 105-2923-M-009-002-MY2, MOHW 105-TDU-B-212-134005]
  3. Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B) from The Featured Areas Research Center Program of the Ministry of Education (MOE) in Taiwan, Republic of China

向作者/读者索取更多资源

A novel EGFR-targeting, thermal-sensitive multifunctional liposome (TSML) was developed based on manganese-doped magnetismengineered iron oxide nanoparticles (MnMEIOs) and gold nanorods (AuNRs) for efficient photothermal therapy and magnetic resonance (MR) imaging. An Erbitux-conjugated TSML (Erb-TSML) was encapsulated with doxorubicin and gold nanorods conjugated with manganese-doped magnetism-engineered iron oxide nanoparticles, for theranostic applications of EGFR-positive tumors. The Erb-TSML selectively targeted EGFRpositive tumors and promoted tumor destruction by laser activation. Using confocal microscopy, MR and optical imaging, we demonstrated that Erb-TSML specifically bound to A431 tumor cells. No signs of major morphological damages to the normal tissues were observed in mice treated with Erb-TSMLand laser, indicating this theranostic platform protected heart against doxorubicin-induced toxicity to normal tissues. These results indicate that the Erb-TSML may be a promising diagnostic and therapeutic platform for EGFR-overexpressing tumors. (C) 2018 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Article Nanoscience & Nanotechnology

Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis

Daniela Rubanova, Svitlana Skoroplyas, Alena Libanska, Eva Randarova, Josef Bryja, Michaela Chorvatova, Tomas Etrych, Lukas Kubala

Summary: This study explored the use of nanocarriers to deliver dexamethasone for treating rheumatoid arthritis. The results showed that this method increased the accumulation of dexamethasone in the arthritic area, had a dose-dependent healing effect, and reduced the accumulation of the RA mediator RANKL. This study provides a feasible strategy for improving rheumatoid arthritis therapy.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2024)

Article Nanoscience & Nanotechnology

Exploiting the ferroaddiction of pancreatic cancer cells using Fe-doped nanoparticles

Thanpisit Lomphithak, Apiwit Sae-Fung, Simone Sprio, Anna Tampieri, Siriporn Jitkaew, Bengt Fadeel

Summary: In this study, iron-doped hydroxyapatite (FeHA) was evaluated as a potential nanomedicine approach for treating PDAC. The results showed that FeHA, in combination with a sublethal dose of the GPX4 inhibitor RSL3, could trigger ferroptosis in KRAS mutant PANC-1 cells while sparing normal human cells. The induction of ferroptosis by FeHA plus RSL3 was found to be dependent on the metalloreductase STEAP3 in PDAC cells.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2024)

Review Nanoscience & Nanotechnology

Mechanism of escape from the antibacterial activity of metal-based nanoparticles in clinically relevant bacteria: A systematic review

Marco Felipe Salas-Orozco, Ana Cecilia Lorenzo-Leal, Idania de Alba Montero, Nuria Patino Marin, Miguel Angel Casillas Santana, Horacio Bach

Summary: The emergence of antibiotic-resistant bacteria in severe infections is a growing concern, particularly in hospital environments. Metal-based nanomaterials have shown potential as an alternative to combat these bacteria, but there is a risk of bacterial resistance and environmental accumulation.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2024)